Last year was not a good one for Dexcom ( DXCM +2.51%). The medical device specialist lagged the market, and even with a bit ...

Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers.

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with Type 2 diabetes and ...

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in a new awareness campaign. The project kicked off Friday, World Diabetes Day ...

DexCom may be a major player in the market for continuous glucose monitors, but that doesn’t means it’s shielded from concerns over slower-than-expected growth.

Interim CEO Jacob Leach reported "third quarter organic revenue growth of 20% compared to the third quarter of 2024" and highlighted "solid share performance in both our U.S. and international ...

The G7 CGM. [Image courtesy of Dexcom] Amid some scrutiny over its latest-generation G7 continuous glucose monitor (CGM), Dexcom (Nasdaq:DXCM) officials addressed claims on the company’s latest ...